Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
Lower screening age calls for more tailored bowel cancer surveillance
2.
findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.
3.
In schizophrenia, sexual dysfunction is frequent.
4.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
5.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
1.
The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment
2.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
3.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
4.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
5.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
4.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation